Effects of Musa cavendish on Selected Physiological Parameters and Haematological Changes in Isoproterenol-Induced Myocardial Infarction in Wistar rats
Article Sidebar
Views | PDF/EPUB Downloads:
78
/ 49
/ 35
Main Article Content
Abstract
Myocardial infarction (MI) is characterized by necrosis of heart muscle cells. Risk factors of MI include hypertension, diabetes mellitus and obesity which are derangements in blood pressure, blood glucose and body weight respectively. Haematological changes play a significant role in the pathophysiology and management of MI. Musa cavendish (MC) is known to exhibit some characteristics which may be protective in MI. The aim of this study was to investigate the effects of MC on selected physiological parameters and deranged haematological indices in isoproterenol (ISP) induced MI in Wistar rats. This study employed an experimental design. Aqueous extraction of MC was carried out. 60 rats were randomly assigned into ten groups (n=6). The groups were Normal control which received distilled water; MC only (100, 200 and 400 mg/kg respectively); MI control (ISP 85 mg/kg); Positive control (ISP + Propranolol 0.5 mg/kg); Aqueous extract of MC (ISP +100, 200 and 400 mg/kg). Blood samples were collected for biochemical analyses. Data analysis utilized one way ANOVA and tukey’s post hoc test with significance set at p<0.05. MC did not cause any significant change in blood pressure, blood glucose and heart rate of healthy animals. There was a decrease in total white blood cells, neutrophils, lymphocytes, monocytes and platelet count and an increase in haemoglobin concentration after 4 weeks of treatment, when compared to control. MC thus reverses ISP induced derangements in PCV, Haemoglobin concentration, platelets, total white blood cell counts, neutrophils, lymphocytes and monocytes.
Downloads
Article Details
Section
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
How to Cite
References
1.Yuyun MF, Sliwa K, Kengne AP, Mocumbi AO, Bukhman G. Cardiovascular Diseases in Sub-Saharan Africa Compared to High-Income Countries: An Epidemiological Perspective. Glob Heart. 2020; 15(1): 15.
2.Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, White HD; Executive Group on behalf of the Joint European Society of Cardiology (ESC)/American College of Cardiology (ACC)/American Heart Association (AHA)/World Heart Federation (WHF) Task Force for the Universal Definition of Myocardial Infarction. Fourth Universal Definition of Myocardial Infarction (2018). J Am Coll Cardiol. 2018; 72(18): 2231-2264.
3.Saito Y, Oyama K, Tsujita K, Yasuda S, Kobayashi Y. Treatment strategies of acute myocardial infarction: updates on revascularization, pharmacological therapy, and beyond. J Cardiol. 2023; 81(2): 168-178.
4.Essien OE, Andy J, Ansa V, Otu AA, Udoh A Coronary artery disease and the profile of cardiovascular risk factors in South South Nigeria: a clinical and autopsy study. Cardiol Res Pract. 2014; 1: 804751.
5.Rakugi H, Yu H, Kamitani A, Nakamura Y, Ohishi M, Kamide K, Nakata Y, Takami S, Higaki J, Ogihara T. Links between hypertension and myocardial infarction. Am Heart J. 1996; 132(1 Pt 2 Su): 213-221.
6.Eitel I, Kubusch K, Strohm O, Desch S, Mikami Y, De Waha S, Gutberlet M, Schuler G, Friedrich MG, Thiele H. Prognostic value and determinants of a hypointense infarct core in T2-weighted cardiac magnetic resonance in acute reperfused ST-elevation–myocardial infarction. Circ Cardiovasc Imaging. 2011; 4(4): 354-362.
7.Carrick D, Haig C, Maznyczka AM, Carberry J, Mangion K, Ahmed N, Yue May VT, McEntegart M, Petrie MC, Eteiba H, Lindsay M. Hypertension, microvascular pathology, and prognosis after an acute myocardial infarction. Hypertens. 2018; 72(3): 720-730.
8. Nedkoff L, Knuiman M, Hung J, Briffa TG. Improving 30-day case fatality after incident myocardial infarction in people with diabetes between 1998 and 2010. Heart. 2015; 101(16): 1318-1324.
9.Nesto RW, Zarich S. Acute myocardial infarction in diabetes mellitus: lessons learned from ACE inhibition. Circulation. 1998; 97(1): 12-5.
10.Johansson S, Rosengren A, Young K, Jennings E. Mortality and morbidity trends after the first year in survivors of acute myocardial infarction: a systematic review. BMC Cardiovasc Disord. 2017; 17(1): 53.
11.Yusuf S, Hawken S, Ounpuu S, Bautista L, Franzosi MG, Commerford P, Lang CC, Rumboldt Z, Onen CL, Lisheng L, Tanomsup S, Wangai P Jr, Razak F, Sharma AM, Anand SS; INTERHEART Study Investigators. Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. Lancet. 2005; 366(9497): 1640-1649.
12.Şaylık F, Çınar T, Hayıroğlu Mİ. Effect of the obesity paradox on mortality in patients with acute coronary syndrome: a comprehensive meta-analysis of the literature. Balkan Med J. 2023; 40(2): 93.
13.Alexandratos, N. The Mediterranean diet in a world context. Public Health Nutr. 2006; 9(1a):111-117.
14.Levy PS, Quigley RL, Gould SA. Acute dilutional anemia and critical left anterior descending coronary artery stenosis impairs end organ oxygen delivery. J Trauma. 1996; 41(3): 416-423.
15.Mamas MA, Kwok CS, Kontopantelis E, Fryer AA, Buchan I, Bachmann MO, Zaman MJ, Myint PK. Relationship Between Anemia and Mortality Outcomes in a National Acute Coronary Syndrome Cohort: Insights From the UK Myocardial Ischemia National Audit Project Registry. J Am Heart Assoc. 2016; 5(11): e003348.
16.Matter MA, Paneni F, Libby P, Frantz S, Stähli BE, Templin C, Mengozzi A, Wang YJ, Kündig TM, Räber L, Ruschitzka F, Matter CM. Inflammation in acute myocardial infarction: the good, the bad and the ugly. Eur Heart J. 2024; 45(2): 89-103.
17.Chihomvu P, Ganesan A, Gibbons S, Woollard K, Hayes MA. Phytochemicals in Drug Discovery-A Confluence of Tradition and Innovation. Int J Mol Sci. 2024; 25(16): 8792.
18.Elufioye TO, Habtemariam S. Drug Development for the Management of Corona Viruses: Insights from Natural Antiviral Agents. 2020; 4(9): 490-511.
19.Speisky H, Shahidi F, Costa de Camargo A, Fuentes J. Revisiting the oxidation of flavonoids: Loss, conservation or enhancement of their antioxidant properties. Antioxidants. 2022; 11(1): 133.
20.Jia JY, Zang EH, Lv LJ, Li QY, Zhang CH, Xia Y, Zhang L, Dang LS, Li MH. Flavonoids in myocardial ischemia-reperfusion injury: Therapeutic effects and mechanisms. Chin Herb Med. 2020;13(1):49-63.
21.Madueke AC, Ugwu DO, Nwanelo VO, Anosike AC, Anajemba RC, Onoh PA. Anti-Ulcerogenic Effect of Unripe Plantain (Musa paradisiaca) Pulp on Indomethacin Induced Ulcer in Wistar Rat. Trop J Nat Prod Res. 2020; 4(10): 784-789.
22.Ahmed MU, Bala U, Umaru IJ. Antioxidant and Alpha Amylase Inhibitory Potential of Methanol Extract of Unripe Musa paradisiaca Fruit with Husk. Trop J Nat Prod Res. 2022; 6(8): 1283-1285
23.Afzal MF, Khalid W, Akram S, Khalid MA, Zubair M, Kauser S, Abdelsamea Mohamedahmed K, Aziz A, Anusha Siddiqui S. Bioactive profile and functional food applications of banana in food sectors and health: a review. Int J Food Prop. 2022; 25(1) :2286-2300
24.Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, Himmelfarb CD, Khera A, Lloyd-Jones D, McEvoy JW, Michos ED, Miedema MD, Muñoz D, Smith SC Jr, Virani SS, Williams KA Sr, Yeboah J, Ziaeian B. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;140(11):e563-e595.
25.Kumar N, Ved A, Yadav RR, Prakash O. A comprehensive review on phytochemical, nutritional, and therapeutic importance of Musa. Int J Curr Res Rev. 2021; 13: 114-124.
26.Umukoro EK, Akponah E, Elijah OB, Moke EG, Ohaju-Obodo, JO, Georgewill, OA. Musa cavendish ameliorates isoproterenol induced renal and hepatic injury in Wistar rats. J Oral Public Health. 2025; 6(7): e1267
27.Nataraj L. Antioxidant capacity and phenolic content of different solvent extract Musa paradisiacal and mustai (Rivea hypocrateriformis). Food Sci Biotech. 2010; 9(5): 1251-1258.
28.Moke EG, Omogbai EKI, Osagie-Eweka SDE, Uchendu AP, Omogbiya AI, Ben-Azu B, Eduviere AT, Edje KE, Umukoro EK, Anachuna KK, Asiwe JN, Ahante E, Oghoghovwe IJ. Co-administration of metformin and/or glibenclamide with losartan reverses NG-nitro-l-arginine-methyl ester-streptozotocin-induced hypertensive diabetes and haemodynamic sequelae in rats. Microvasc Res. 2023;147:104497.
29.Ble-Castillo JL, Aparicio-Trápala MA, Francisco-Luria MU, Córdova-Uscanga R, Rodríguez-Hernández A, Méndez JD, Díaz-Zagoya, JC. Effects of native banana starch supplementation on body weight and insulin sensitivity in obese type 2 diabetics. Int J Environ Res Public Health. 2010; 7(5): 1953-1962.
30.Blood Pressure Lowering Treatment Trialists' Collaboration. Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. Lancet. 2021; 397(10285): 1625-1636.
31.Lin HL, Tseng YH, Yeh CC, Chen YM, Shen KP. Effect evaluation of banana on improving hyperglycemia and hypertension in diabetic spontaneously hypertensive rats. Nat Prod Comm, 2023; 18(11):1-10
32.Filippini T, Naska A, Kasdagli MI, Torres D, Lopes C, Carvalho C, Moreira P, Malavolti M, Orsini N, Whelton PK, Vinceti M. Potassium Intake and Blood Pressure: A Dose-Response Meta-Analysis of Randomized Controlled Trials. J Am Heart Assoc. 2020; 9(12):e015719.
33. Yanti, E., Nofia, VR. The effect of mosquito banana (Musa paradisiaca) on blood pressure in hypertension patients.In Proceeding International Conference Syedza Saintika. 2020; 1 (1)
34.Rafi IK, Sanyal A, Hoque M. The Impact of Banana Consumption on Bangladeshi Rickshaw Pullers' Assessing Cholesterol, Liver and Blood Pressure Functions. Middle East Res J Biological Sci. 2023; 3(2): 24-28.
35.Padda J, Khalid K, Hitawala G, Batra N, Pokhriyal S, Mohan A, Cooper AC, Jean-Charles G., Pokhriyal SC. Acute anemia and myocardial infarction. Cureus. 2021; 13(8).
36.Pei J, Wang X, Chen P, Zheng K, Hu X. Hb Levels and Sex Differences in Relation to Short-Term Outcomes in Patients With Acute Myocardial Infarction. Front Cardiovasc Med. 2021; 8: 653351.
37.Carson JL, Brooks MM, Hébert PC, Goodman SG, Bertolet M, Glynn SA, Chaitman BR, Simon T, Lopes RD, Goldsweig AM, DeFilippis AP, Abbott JD, Potter BJ, Carrier FM, Rao SV, Cooper HA, Ghafghazi S, Fergusson DA, Kostis WJ, Noveck H, Kim S, Tessalee M, Ducrocq G, de Barros E Silva PGM, Triulzi DJ, Alsweiler C, Menegus MA, Neary JD, Uhl L, Strom JB, Fordyce CB, Ferrari E, Silvain J, Wood FO, Daneault B, Polonsky TS, Senaratne M, Puymirat E, Bouleti C, Lattuca B, White HD, Kelsey SF, Steg PG, Alexander JH; MINT Investigators. Restrictive or Liberal Transfusion Strategy in Myocardial Infarction and Anemia. N Engl J Med. 2023; 389(26): 2446-2456.
38.Orrico F, Laurance S, Lopez AC, Lefevre SD, Thomson L, Möller MN, Ostuni MA. Oxidative Stress in Healthy and Pathological Red Blood Cells. Biomolecules. 2023; 13(8): 1262.
39. Anker SD, Voors A, Okonko D, Clark AL, James MK, von Haehling S, ... & Dickstein K. Prevalence, incidence, and prognostic value of anaemia in patients after an acute myocardial infarction: data from the OPTIMAAL trial. Eur Heart J. 2009; 30(11): 1331-1339.
40.Bolińska S, Sobkowicz B, Zaniewska J, Chlebińska I, Boliński J, Milewski R, ... & Musiał W. The significance of anaemia in patients with acute ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Pol Heart J (Kardiologia Polska). 2011; 69(1): 33-39.
41.Osinowo O, Odubo TC, Izah SC. Hematopoietic Potentials of Musa paradisiaca Stem Sap. ES General. 2024; 6: 1139.
42.e Silva AF, Copatti CE, de Oliveira EP, Bonfá HC, de Melo FVST, de Silva Camargo AC, Melo JFB. Effects of whole banana meal inclusion as replacement for corn meal on digestibility, growth performance, haematological and biochemical variables in practical diets for tambaqui juveniles (Colossoma macropomum). Aquac Rep. 2020; 17: 100307.
43.Amraotkar AR, Song DD, Otero D, Trainor PJ, Ismail I, Kothari V, Singh A, Moore IV JB, Rai SN, DeFilippis AP. Platelet count and mean platelet volume at the time of and after acute myocardial infarction. Clin Appl Thromb Hemost. 2017; 23(8): 1052-1059.
44.Chu SG, Becker RC, Berger PB, Bhatt DL, Eikelboom JW, Konkle B, Mohler ER, Reilly MP, Berger JS. Mean platelet volume as a predictor of cardiovascular risk: a systematic review and meta‐analysis. J Thromb Hemost. 2010; 8(1): 148-156.
45.Azab B, Torbey E, Singh J, Akerman M, Khoueiry G, Mcginn Jr JT, Widmann WD, Lafferty J. Mean platelet volume/platelet count ratio as a predictor of long-term mortality after non-ST-elevation myocardial infarction. Platelets. 2011; 22(8): 557-566.
46.Fuentes E, Moore-Carrasco R, de Andrade Paes AM, Trostchansky A. Role of Platelet Activation and Oxidative Stress in the Evolution of Myocardial Infarction. J Cardiovasc Pharmacol Ther. 2019; 24(6): 509-520.
47.Avramakis G, Papadimitraki E, Papakonstandinou D, Liakou K, Zidianakis M, Dermitzakis A, Mikhailidis DP, Ganotakis ES. Platelets and white blood cell subpopulations among patients with myocardial infarction and unstable angina. Platelets. 2007; 18(1): 16-23.
48.Dragu R, Huri S, Zukermann R, Suleiman M, Mutlak D, Agmon Y, Kapeliovich M, Beyar R, Markiewicz W, Hammerman H, Aronson D. Predictive value of white blood cell subtypes for long-term outcome following myocardial infarction. Atherosclerosis. 2008;196(1):405-412.
49.Shen XH, Chen Q, Shi Y, Li HW. Association of neutrophil/lymphocyte ratio with long-term mortality after ST elevation myocardial infarction treated with primary percutaneous coronary intervention. Chin Med J (Engl). 2010; 123(23): 3438-3443.
50.Huse C, Anstensrud AK, Michelsen AE, Ueland T, Broch K, Woxholt S, Yang K, Sharma K, Tøllefsen IM, Bendz B, Amundsen BH, Damås JK, Berg ES, Bjørkelund E, Quiles-Jiménez A, Bjerkeli V, Bendz C, Kleveland O, Stensaeth KH, Opdahl A, Kløw NE, Andersen GØ, Wiseth R, Halvorsen B, Gullestad L, Seljeflot I, Aukrust P, Osnes L, Dahl TB. Interleukin-6 inhibition in ST-elevation myocardial infarction: Immune cell profile in the randomised ASSAIL-MI trial. EBioMedicine. 2022; 80:104013.
51.Peet C, Ivetic A, Bromage DI, Shah AM. Cardiac monocytes and macrophages after myocardial infarction. Cardiovasc Res. 2020; 116(6): 1101-1112.
52.Tudurachi BS, Anghel L, Tudurachi A, Sascău RA, Stătescu C. Assessment of Inflammatory Hematological Ratios (NLR, PLR, MLR, LMR and Monocyte/HDL-Cholesterol Ratio) in Acute Myocardial Infarction and Particularities in Young Patients. Int J Mol Sci. 2023; 24(18): 14378.